Fig. 2.

Adjusted LS Mean (95% CI) Change from Baseline in EQ-VAS. Repeated measures mixed model with cohort by objective response interaction, cohort by week interaction controlling for baseline EQ-VAS comorbidity index, ECOG at baseline, age, AJCC stage, autoimmune comorbidity, therapy objective response to therapy. AJCC American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, CI confidence interval, GHS/QoL global health quality of life scale, LS least squares, PEMBRO pembrolizumab, IPI + NIVO ipilimumab and nivolumab, CI confidence interval, VAS Quality of life visual analog scale, PEMBRO pembrolizumab, IPI + NIVO ipilimumab and nivolumab